ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 25,600 shares, a decrease of 34.4% from the November 30th total of 39,000 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is presently 0.0 days.

ZyVersa Therapeutics Stock Down 6.5 %

NASDAQ:ZVSA opened at $1.15 on Friday. The company has a 50 day moving average price of $1.38 and a 200-day moving average price of $2.59. ZyVersa Therapeutics has a 1-year low of $0.98 and a 1-year high of $25.00.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.